Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8497448 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8499024 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8498240 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8498567 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8499782 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8498688 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8495744 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL1047918 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL8497303 | 1.00 | CA2 (0.53) | CA2TAAR1CYP4F2CYP4A11GAA | |
| SCHEMBL1287204 | 0.98 | CA2 (0.52) | CA2TAAR1CYP4F2CYP4A11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10343982-B2 | Compounds and mesogenic media | MERCK PATENT GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| CN-103958518-B | Heterocyclyl pyridyl pyrazoles/heterocyclyl pyrimidines base pyrazoles | 拜耳知识产权有限责任公司 | 2017-07-04 | — | — | CN | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-3049506-B1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-6071899-A | Azetidinone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| WO-1996013484-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-09 | — | — | WO | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229795-A1 | COMPOUNDS AND MESOGENIC MEDIA | MTX1, NEFM, MTX2 | CA2 1649/4885TAAR1 227/4885CYP4F2 294/4885 |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA2 3091/4885TAAR1 1385/4885CYP4F2 177/4885 |
| US-10343982-B2 | Compounds and mesogenic media | MTX1, NEFM, MTX2 | CA2 1649/4885TAAR1 227/4885CYP4F2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.